CENTESSA PHARMACEUTICALS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc – CNTA
NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 28, 2022 to file lead plaintiff applications in a securities class action lawsuit against Centessa Pharmaceuticals plc (NasdaqGS: CNTA), if they purchased or otherwise acquired the Company’s securities between May 28, 2021 and June 1, 2022, inclusive (the “Class Period”) and/or purchased or otherwise acquired the Company’s American Depositary Shares (“ADSs”) pursuant to the Company’s May 2021 initial public offering (the “IPO”). This action is pending in the United States District Court for the Central District of California.
What You May Do
If you purchased securities or ADSs of Centessa as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-cnta/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by November 28, 2022.
About the Lawsuit
Centessa and certain of its executives are charged with failing to disclose material information during the Class Period and/or in the Registration Statement and Prospectus issued in conjunction with the initial public offering, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) lixivaptan, the Company’s drug product, was less safe than the Company had represented; (ii) the Company overstated lixivaptan’s clinical effectiveness and commercial viability; (iii) ZF874, another of the Company’s drug products, was less safe than the Company had represented; (iv) the Company overstated ZF874’s clinical effectiveness and commercial viability while downplaying the drug’s safety issues; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
The case is Fernandes v. Centessa Pharmaceuticals Plc, et al., No. 22-cv- 07030.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contacts
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com1-877-515-1850
